DINORA INC

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2004

Legal Domicile

Principal Officer

VALORIE THOMPSON

Phone

2022447422

Tax Period

2023-01-01 to 2023-12-31

DINORA INC, founded in 2004, is a small nonprofit in the Medical Research sector that reported $226K in total revenue in fiscal year 2023. Revenue surged 222% from the prior year, signaling strong growth momentum. The organization ran a surplus of $54K, a strong 24% operating margin.

Mission

TO SUPPORT CHARITABLE AND EDUCATIONAL ACTIVITIES THAT PROMOTE THE CLINICAL APPLICATION OF UNIQUE THEORIES AND THERAPIES TO TREAT, PREVENT AND CURE ARTHRITIS THROUGH FUNDING STUDIES EDUCATIONAL SEMINARS AND MEDICAL PUBLICATIONS THAT PROMOTE NEW THERAPIES AND TREATMENT

Program Service Accomplishments

Program 1

Expenses: $15,050 Revenue: $4,000

MYOSITIS WORKING GROUP - THE OMERACT MYOSITIS WORKING GROUP IS AN INTERNATIONAL COLLABORATION OF WELL-KNOWN CLINICAL RESEARCHERS, PATIENTS, AND STATISTICIANS. THE AIM OF THE WORKING GROUP IS TO...

MYOSITIS WORKING GROUP - THE OMERACT MYOSITIS WORKING GROUP IS AN INTERNATIONAL COLLABORATION OF WELL-KNOWN CLINICAL RESEARCHERS, PATIENTS, AND STATISTICIANS. THE AIM OF THE WORKING GROUP IS TO DEVELOP OUTCOME MEASURES BASED ON PATIENTS' EXPERIENCES AND TO VALIDATE THESE MEASURES THOROUGHLY TO USE IN CLINICAL TRIALS.

Program 2

Expenses: $43,195 Revenue: $43,195

INTERNATIONAL RHEUMATOLOGY COLLEAGUES DINNER - INITIATED IN 2000, THE IRC DINNER PROVIDES THE OPPORTUNITY FOR RHEUMATOLOGISTS TO BECOME UPDATED ON CURRENT CLINICAL RESEARCH ACTIVITIES. GIVEN THE...

INTERNATIONAL RHEUMATOLOGY COLLEAGUES DINNER - INITIATED IN 2000, THE IRC DINNER PROVIDES THE OPPORTUNITY FOR RHEUMATOLOGISTS TO BECOME UPDATED ON CURRENT CLINICAL RESEARCH ACTIVITIES. GIVEN THE RANGE OF RHEUMATOLOGIC DISORDERS, AND THE EVER-INCREASING NUMBER OF DIAGNOSTIC PROCEDURES AND TREATMENT OPTIONS, IT IS IMPORTANT TO PROVIDE CLINICIANS WITH INFORMATION TO UTILIZE THE MOST EFFECTIVE TREATMENTS TO ENSURE OPTIMAL PATIENT OUTCOMES. IT IS ALSO IMPORTANT FOR CLINICIANS AND RESEARCHERS TO ENHANCE THEIR KNOWLEDGE OF RESEARCH CURRENTLY BEING CONDUCTED AND THE BREAKTHROUGHS IN UNDERSTANDING THE UNDERLYING PATHOPHYSIOLOGY OF VARIOUS RHEUMATIC DISEASES WHICH MAY LEAD TO THE AVAILABILITY OF NEW TARGETED THERAPIES.

Program 3

Expenses: $41,708 Revenue: $109,991

PROACTIVE - INITIATING AND SUPPORTING A PUBLIC PRIVATE, PRE-COMPETITIVE COLLABORATION AMONG A BROAD SPECTRUM OF STAKEHOLDERS, INCLUDING ACADEMIA, GOVERNMENT AGENCIES, INDUSTRY, PROFESSIONAL...

PROACTIVE - INITIATING AND SUPPORTING A PUBLIC PRIVATE, PRE-COMPETITIVE COLLABORATION AMONG A BROAD SPECTRUM OF STAKEHOLDERS, INCLUDING ACADEMIA, GOVERNMENT AGENCIES, INDUSTRY, PROFESSIONAL ORGANIZATIONS, AND PATIENT ORGANIZATIONS WITH THE GOAL OF SHARING DATA AND INNOVATIVE THINKING ABOUT THE DEVELOPMENT OF OSTEOARTHRITIS (OA) OUTCOME MEASURES FOR CLINICAL TRIALS OF THERAPIES AIMED AT SLOWING OA PROGRESSION.THE FOOD AND DRUG ADMINISTRATION APPROVED PROACTIVE'S APPLICATION SEEKING PARTICIPATION BY INDIVIDUALS FROM THE CENTER FOR DRUG EVALUATION AND RESEARCH (CDER) TO ENGAGE IN THE ACTIVITIES OF THE CONSORTIUM.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $0

Program Service Revenue $225,906

Investment Income $74

Other Revenue $0

TOTAL REVENUE $225,980

Expense Breakdown

Grants Paid $0

Salaries & Benefits $0

Fundraising Expenses $0

Program Expenses $168,673

Other Expenses $172,119

TOTAL EXPENSES $172,119

Year-over-Year Comparison

	2023	2022	Change
Revenue	$225,980	$70,074	+2.2%
Expenses	$172,119	$31,021	+4.5%
Net Income	$53,861	$39,053	+0.4%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

N/A

Governance Policies

✓ Conflict of Interest Policy

✗ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
VALORIE THOMPSON	DIRECTOR	1.00	Officer Director	$0	$0	$0
ANTHONY A SARIDAKIS	SECRETARY/TREASURER	1.00	Officer Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2023	$225,980	$172,119	$935,882	$53,861
2022	$70,074	$31,021	$882,021	$39,053
2021	$151,074	$152,612	$842,968	$-1,538
2020	$5,288	$53,414	$844,506	$-48,126
2019	$407,868	$243,113	$892,632	$164,755
2018	$133,586	$146,262	$727,719	$-12,676